Northway Biotech founder Vladas Algirdas Bumelis spoke to European Biotechnology about the company’s €61m investment in a new Vilnius manufacturing center built specifically for cell therapies and personalized medicines. The story explores how the CDMO is positioning itself at the forefront of a shifting pharmaceutical model, one where entire manufacturing processes may be dedicated to a single patient, and where speed, segregation and supply‑chain consolidation become critical enablers for next‑generation therapies. With ten production lines currently undergoing qualification and manufacturing authorisation expected within six months, Northway is already onboarding development projects and preparing clients to transition into GMP as soon as approval lands.

Bumelis outlines how the facility’s design is intended to remove traditional bottlenecks in CAR‑T and gene therapy supply chains. The piece highlights Lithuania’s strategic backing, including €48m in national development bank financing, and frames the plant as a cornerstone of the country’s ambition to grow life sciences to 5% of GDP by 2030. Together, the investment, infrastructure and co‑located capabilities illustrate a broader bet: that industrial‑scale personalised medicine will move out of hospital settings and into purpose‑built CDMOs capable of running many small processes in parallel.

Read the full story here.